Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review

Overview of attention for article published in Frontiers in oncology, January 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 4 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 23,814 followers.

Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review https://t.co/CPAsRKfwV6 https://t.co/4EOPlnmTK3

12 Jan 2023

Reply Repost Favourite

New research: Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review: There is uncertainty regarding the… https://t.co/D

10 Jan 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.